1-8 of 8
Julie Blædel
Close
Sort by
Journal Articles

Efficacy of Subcutaneous Epcoritamab Vs Tisa-Cel in R/R LBCL CAR T-Naive and CAR T-Eligible Patients: An Indirect Comparison

Gilles Salles, Christopher P. Fox, Anthony Wang, Kavita Sail, Abualbishr Alshreef, Michael Moran, Alex Mutebi, Julie Blaedel, Viktor Chirikov, Wei-Jhih Wang, Catherine Thieblemont
Journal: Blood
Blood (2023) 142 (Supplement 1): 1733.
https://doi.org/10.1182/blood-2023-180047
Published: 2023
Journal Articles

Transcriptomic Comparison of Non-Hodgkin Lymphomas in Relapsed/Refractory Versus Newly Diagnosed Patients Using Single FFPE Slides

Omar Jabado, Christopher Chiu, Matthew Loya, Manling Ma-Edmonds, David Soong, Anantharaman Muthuswamy, Mahesh Bachu, Nicole Bottrel, Han Si, Jimin Zhang, Monica Wielgos-Bonvallet, Julie Blædel, Erin Henitz, Brandon Higgs, Kate Sasser, Suzana Couto, Maria Jure-Kunkel, Mark Fereshteh
Journal: Blood
Blood (2022) 140 (Supplement 1): 6424–6425.
https://doi.org/10.1182/blood-2022-159384
Published: 2022
Journal Articles

Improvements in Lymphoma Symptoms and Health-Related Quality of Life in Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Subcutaneous Epcoritamab (EPCORE NHL-1)

Tycel Phillips, Pieternella Lugtenburg, Anupama Kalsekar, Alex Mutebi, Anthony Wang, Julie Blaedel, Katherine Kosa, Susan Martin, Mariana Sacchi, Catherine Thieblemont
Journal: Blood
Blood (2022) 140 (Supplement 1): 8022–8023.
https://doi.org/10.1182/blood-2022-159544
Published: 2022
Journal Articles

Subgroup Analysis of Patients with Biochemical or Symptomatic Relapse at the Time of Enrollment in the Endeavor Study

Philippe Moreau, David S Siegel, MD PhD, Hartmut Goldschmidt, MD, Ruben Niesvizky, MD, Sara Bringhen, MD, Robert Z Orlowski, MD PhD, Julie Blaedel, Zhao Yang, Meletios A Dimopoulos, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3243.
https://doi.org/10.1182/blood-2018-99-112571
Published: 2018
Journal Articles

Carfilzomib in Relapsed or Refractory Multiple Myeloma Patients with Early or Late Relapse Following Prior Therapy: An Analysis of Overall Survival in Subgroups from the Randomized Phase 3 Aspire and Endeavor Trials

Maria-Victoria Mateos, MD PhD, Hartmut Goldschmidt, MD, Jesus F San-Miguel, MD PhD, Julie Blaedel, Mihaela Obreja, Zhao Yang, Zsolt Szabo, Xavier Leleu, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1964.
https://doi.org/10.1182/blood-2018-99-112189
Published: 2018
Journal Articles

Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial

A. Keith Stewart, MBChB, MBA, David Siegel, MD PhD, Heinz Ludwig, MD, Thierry Facon, MD, Hartmut Goldschmidt, MD, Andrzej J. Jakubowiak, MD, Jesus F. San Miguel, MD, Mihaela Obreja, Julie Blaedel, Meletios A. Dimopoulos
Journal: Blood
Blood (2017) 130 (Supplement 1): 743.
https://doi.org/10.1182/blood.V130.Suppl_1.743.743
Published: 2017
Journal Articles

Carfilzomib in Relapsed or Refractory Multiple Myeloma Patients with Early or Late Relapse Following Prior Therapy: A Subgroup Analysis of the Randomized Phase 3 Aspire and Endeavor Trials

Maria-Victoria Mateos, Hartmut Goldschmidt, MD, Jesus F San Miguel, MD PhD, Joseph Mikhael, MD, Lucy DeCosta, MSc, Lifen Zhou, Mihaela Obreja, Julie Blaedel, Zsolt Szabo, MD, Xavier Leleu, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3120.
https://doi.org/10.1182/blood.V130.Suppl_1.3120.3120
Published: 2017
Journal Articles

Relapsed or Refractory Multiple Myeloma Patients Treated with Second-Line Carfilzomib and Categorized By Prior Exposure to Bortezomib: A Subgroup Analysis of the Randomized Phase 3 Aspire and Endeavor Trials

Maria-Victoria Mateos, Hartmut Goldschmidt, MD, Jesus F San Miguel, MD PhD, Joseph Mikhael, MD, Lifen Zhou, Mihaela Obreja, Julie Blaedel, Karim Saad Iskander, Xavier Leleu, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1840.
https://doi.org/10.1182/blood.V130.Suppl_1.1840.1840
Published: 2017